YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Summit Therapeutics SMMT is expanding the development of its sole investigational drug, ivonescimab, through a new clinical collaboration with AstraZeneca AZN and its Japan-based partner Daiichi Sankyo. Under the agreement, ivonescimab wil…
In late September and early October 2026, AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced a series of clinical collaboration agreements to test ivonescimab in combination with Datroway (datopotamab deruxtecan) and sonesit…
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, expanded its cancer-drug collaboration with Summit Therapeutics as U.S. shares edge a bit lower at $157.10 at 11.35am ET on Octob…
Daiichi Sankyo (TSE:4568) is again in focus after IHH Healthcare appealed a Tokyo District Court judgment tied to the Fortis Healthcare acquisition. The appeal was filed to the Tokyo High Court, extending longstanding legal disputes that c…
[The answers lie in the evidence] PixelsEffect/iStock via Getty Images * Daiichi Sankyo (DSKYF [https://seekingalpha.com/symbol/DSKYF]) and AstraZeneca entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT [h…
TOKYO, October 02, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopot…
Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer MIAMI, October 02, 2026--(BUSINESS WIRE)--Summit Therapeutic…
Daiichi Sankyo Company has seen its share price fall over the past few years, so the key issue now is whether the current market value lines up with the cash the business is expected to generate. With investors also weighing fresh data aro…
Daiichi Sankyo Company (TSE:4568) is back in focus after it voluntarily withdrew a U.S. accelerated approval filing for ifinatamab deruxtecan, while larger Phase 3 trials for the drug continue across several cancer indications. The latest…
This article first appeared on GuruFocus. A Deep Dive into the Pharmaceutical Giant's Upcoming Payout and Long-Term Dividend Sustainability Daiichi Sankyo Co Ltd (DSKYF) recently announced a total dividend of $0.31 per share, with the ex-d…
Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after plati…
It was reported on September 25 that the U.S. FDA has accepted and granted Priority Review to AstraZeneca PLC (NYSE:AZN)'s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) in combination with enfortumab vedotin (E…
Over the past decade, AstraZeneca AZN has built a broad oncology franchise spanning multiple cancer types, including lung, breast, blood, gastrointestinal and genitourinary cancers. The segment contributes roughly 46% of total revenues and…
[Lung cancer inside the human lungs. 3d illustration] Mohammed Haneefa Nizamudeen/iStock via Getty Images * Merck (MRK [https://seekingalpha.com/symbol/MRK]) has voluntarily withdrawn a BLA for its antibody-drug conjugate I-DXd (ifinatamab…
RAHWAY, N.J., September 25, 2026--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canad…
TOKYO, September 25, 2026--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, ifin…
AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival (PFS) in patie…
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca's Enhertu has the potential to become a new stan…
AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-yea…
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, secured a major access win for Enhertu in England after the NHS reversed an earlier cost-effectiveness rejection, Reuters reporte…
Daiichi Sankyo and AstraZeneca's Enhertu, in combination with pertuzumab, was approved in the European Union in September 2026 for first-line treatment of unresectable or metastatic HER2 positive breast cancer, triggering a US$100 million…
6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy AstraZeneca and Daiichi Sankyo's ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial…
Represents a six-month improvement in median progression-free survival versus pembrolizumab plus chemotherapy Daiichi Sankyo and AstraZeneca's Enhertu is the first HER2 directed medicine to delay disease progression over standard of care i…
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener ha…
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10…
TOKYO, August 27, 2026--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS1025 in adult patients with advanced or metastatic solid tumors with disease progression on or after at least one prio…
TOKYO, August 26, 2026--(BUSINESS WIRE)--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (d…
MUNICH, August 24, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business withi…
TOKYO, August 24, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's oncology and specialty…
Cosmos Health Inc. Innova is backed by leading investors and healthcare groups: Alkhabeer Capital, with more than $2.5 billion AUM; Tamer Group, a pharma manufacturing partner to Astellas and Daiichi Sankyo; and Cigalah Group, whose health…
Daiichi Sankyo and AstraZeneca's Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this setting Data to be presented at an upcoming medical meeting…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Daiichi Sankyo Company (TSE:4568) has signed an exclusive commercialization agreement with Innovent Biologics for acute myel…
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have…
* Daiichi Sankyo Company press release [https://seekingalpha.com/pr/20602581-daiichi-sankyo-reports-first-quarter-fiscal-year-2026-financial-results] (DSNKY [https://seekingalpha.com/symbol/DSNKY]): Q1 Revenue of ¥574.78B. * Full fiscal ye…
Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway® Fiscal year 2026 guidance for revenue and operating profit revised upward Conference call to take place on Friday, July 31 at 5:30 pm Japan Standa…